NASDAQ · GRDX

GridAI Technologies Corp.

$3.04 -$0.31 (-9.25%) 1D Market open

Key Metrics

$23.52M
Market cap
P/E · TTM
$74.46K
Revenue · TTM
−$8.57M
Net income
EPS · TTM $-1.93
Dividend yield
Free cash flow
Beta · 1Y 2.08
EBITDA · TTM −$8.87M
Gross margin -1,707.2%

The Story So Far

LAST 6 MONTHS PRIMARY SOURCES ONLY
  • Jul 24
    From its Jun 1 high, the share price fell 55%.

    Peak close $6.80 on Jun 1; trough close $3.04 on Jul 24. The drawdown is the fact — the chapters around it are the context.

    RECEIPT: PRICE SERIES, PEAK-TO-TROUGH -55%
  • Jul 16
    Money rotated out of high-beta cohorts market-wide.

    High-beta names lagged the blue-chips by 18.6 points over ten sessions around this date. Stocks in that cohort weren't falling alone — they fell together.

    RECEIPT: ROTATION GAUGE, LIVE
  • Jun 1
    The stock moved +21.2% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Jun 1
  • Apr 1
    The stock moved +22.8% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Apr 1

The story updates itself as events post · The wolf reports; you decide

Snapshot

Market cap$23.52M
Enterprise value
Shares outstanding7.0M
52-wk range$1.87 – $6.93
Avg volume · 20D112.5K
Net cash
Book value / share$5.30
IndustryPharmaceutical Preparations
ExchangeNASDAQ
About GridAI Technologies Corp.
IPO dateOct 11, 2016
Employees2

GridAI Technologies Corp, formerly known as Entero Therapeutics Inc, is a late clinical-stage biopharmaceutical company focused on the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases.

Wolf Grade COMING SOON

The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.

Valuation

P/E
P/S315.94
P/FCF
EV/EBITDA
EV/Sales
Graham №

Profitability

Gross -1,707.2%
Operating -12,662.3%
Net -11,512.0%
FCF
ROE / ROIC -86.9% · -101.6%

Financial Health

Current ratio0.16
Quick ratio
Debt / equity
Debt / EBITDA
Net cash
Working capital−$13.65M

Cash Flow · TTM

Operating CF −$6.67M
Capex
Free cash flow
Buybacks
Dividends paid
Shareholder yield

Piotroski F-Score

2 / 9
Weak fundamentals · 2 of 9 signals passing

Altman Z-Score

-6.5
Distress zone (< 1.81) · elevated risk

Graham Number vs Price

Requires positive earnings and book value
Fundamentals through 2026-03-31 · computed by TickerWolf from SEC filings